• Five women with primary, major, bipolar affective disorder, characterized by rapid mood cycles and nonresponsiveness to conventional drug treatments, including lithium carbonate, were given low doses (2.5 to 10.0 mg/24 hr) of clorgyline, a selective inhibitor of monoamine oxidase type A. In four patients, clorgyline, alone or in combination with lithium carbonate, prolonged the duration and lessened the severity of mood cycles. One patient experienced prolonged manias while receiving clorgyline therapy. Clorgyline-induced remissions have lasted from three to more than 12 months.
Potter WZ, Murphy DL, Wehr TA, Linnoila M, Goodwin FK. Clorgyline: A New Treatment for Patients With Refractory Rapid-Cycling Disorder. Arch Gen Psychiatry. 1982;39(5):505–510. doi:10.1001/archpsyc.1982.04290050001001
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.